Last reviewed · How we verify
AMV564
At a glance
| Generic name | AMV564 |
|---|---|
| Sponsor | Amphivena Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of AMV564 in Subjects With Advanced Solid Tumors (PHASE1)
- Study of AMV564 in Patients With AML (PHASE1)
- A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |